> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approval Remains Pending For Intellia Therapeutics' Treatment As Stock Plunges 8% After Clinical Update
- URL: https://www.bullished.co/fda-approval-remains-pending-for-intellia-therapeutics-treatment-as-stock-plunges-8-after-4c1acd0f/
- Published: 2026-11-13T21:20:05.000Z
- Updated: 2026-11-13T21:20:05.000Z
- Description: Coverage and center readiness would determine whether the launch plan's envisioned wait of three to six months between potential approval and first treatments and revenue holds.
- Author: Matteo Parrino
- Tags: Markets, NTLA, Industry: Healthcare

[Intellia Therapeutics](https://www.bullished.co/tag/ntla/), which develops gene-editing treatments, plunged 8.1% to $9.70 at Friday's close, erasing $119 million in market value after Thursday's clinical update. Its experimental treatment for recurring swelling attacks remains [awaiting FDA approval](https://www.nature.com/articles/d41586-026-03705-9?ref=bullished.co).

## Fewer Attacks, Infusion Reactions

Intellia presented the update on lonvoguran ziclumeran, known as lonvo-z, with an [SEC filing](https://www.sec.gov/Archives/edgar/data/0001652130/000119312526458422/ntla-20261112.htm?ref=bullished.co) Thursday. The treatment targets hereditary angioedema, a disorder that causes painful swelling that can become dangerous.

Compared with the monthly attack frequency recorded during their previous preventive treatment, the 35 recipients in the late-stage trial experienced 81% fewer attacks per month. Across 93 people given the 50-milligram dose, 51 had infusion reactions.

Potential approval would be followed by a wait of [three to six](https://www.sec.gov/Archives/edgar/data/0001652130/000119312526458422/ntla-20261112.htm?ref=bullished.co) months before first treatments and revenue under Intellia's illustrative launch plan. Insurance coverage and treatment centers' readiness would determine whether the company begins treating patients within that window.

## A Single-Infusion Gene-Editing Bet

Intellia uses CRISPR, a technology for changing DNA, to develop treatments for severe diseases. Its lead experimental programs are designed to be given through a single intravenous infusion and are in late-stage clinical development.

Alongside lonvo-z, Intellia is developing nexiguran ziclumeran for transthyretin amyloidosis, which harms organs and tissues through protein buildup. Partner Regeneron shares approximately 25% of worldwide development costs and commercial profits for that program.

Intellia runs studies across multiple countries and develops treatments both independently and with partners. Its technology-licensing arrangements include payments, royalties and shared costs.

Safety scrutiny has affected other Intellia programs. The FDA stopped two studies last year after a participant suffered liver damage and died; it [lifted those holds](https://www.nature.com/articles/d41586-026-03705-9?ref=bullished.co) this year with additional safeguards.

## A Month Of Sharp Drops

Friday's decline left Intellia with a market value of about $1.4 billion. The original report described the stock as on pace for its fourth decline of 7% or more this month.

At Thursday's close, shares were up 17% year-to-date, compared with an 11% gain for the S&P 500\. Intellia had nevertheless fallen 16% over the previous month.

In its earlier quarterly filing, Intellia reported [revenue of $7.2 million](https://www.sec.gov/Archives/edgar/data/1652130/000119312526449862/ntla-20260930.htm?ref=bullished.co), down 48% from a year earlier, and a $127.5 million net loss.

Saturday's scheduled presentations will cover lonvo-z's [four-year safety](https://www.globenewswire.com/news-release/2026/11/12/3401802/0/en/intellia-therapeutics-presents-additional-positive-clinical-and-patient-reported-data-for-lonvoguran-ziclumeran-lonvo-z-at-acaai-2026.html?ref=bullished.co) and durability results, including whether patients remain free of attacks without preventive medication.

### Sources

- [Novel CRISPR therapy is poised to gain first FDA approval to alter genes inside the body | Nature](https://www.nature.com/articles/d41586-026-03705-9?ref=bullished.co) — nature.com
- [Intellia Therapeutics Presents Additional Positive Clinical](https://www.globenewswire.com/news-release/2026/11/12/3401802/0/en/intellia-therapeutics-presents-additional-positive-clinical-and-patient-reported-data-for-lonvoguran-ziclumeran-lonvo-z-at-acaai-2026.html?ref=bullished.co) — globenewswire.com
- [The company's filing (Intellia Therapeutics)](https://www.sec.gov/Archives/edgar/data/0001652130/000119312526458422/ntla-20261112.htm?ref=bullished.co) — SEC filing
- [Intellia Therapeutics — Form 10-Q for the quarter ended 2026-09-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/1652130/000119312526449862/ntla-20260930.htm?ref=bullished.co) — SEC EDGAR

### More on Intellia Therapeutics

- [Intellia's One-Time Gene Treatment Cuts Attacks 81% Versus Patients' Previous Preventive Drugs](https://www.bullished.co/intellias-one-time-gene-treatment-cuts-attacks-81-versus-patients-previous-preventive-91734633/)
- [State Street Holds 5.6% Of Intellia As The Company Prepares For A Potential Drug Launch](https://www.bullished.co/state-street-holds-5-6-of-intellia-as-the-company-prepares-for-a-potential-drug-launch-cf57c32c/)

[All Intellia Therapeutics (NTLA) coverage →](https://www.bullished.co/tag/ntla/)